The safety of the diabetes drug Avandia looked increasingly suspect late last month after two major studies found that it raises the risk of cardiovascular ailments. Then a third study seemed to exonerate Avandia, sowing more confusion. Expert advisers to the Food and Drug Administration will soon deliver a more definitive judgment, but at this point patients should probably be asking their doctors about alternatives.
Avandia was approved in 1999 to help diabetics control their blood sugar levels. For the past three years a debate has raged over whether it increases the risk of cardiovascular problems. The evidence has been mixed, and the F.D.A. has left it on the market while beefing up the warning labels.
Now a study in the Journal of the American Medical Association has found that elderly patients given the drug had higher risks of stroke, heart failure and death than those given Actos, another drug in the same class. This study warrants particular attention because of its huge size: it analyzed records for more than 227,000 Medicare patients who took either Avandia or Actos. A second study — in the Archives of Internal Medicine, also published by the A.M.A. — found that Avandia increased the risk of heart attack by 28 to 39 percent.
Read the rest of the commentary here.



i know what you mean..this med is dangerous